Brexucabtagene autoleucel for the treatment of relapsed/refractory mantle cell lymphoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Brexucabtagene autoleucel for the treatment of relapsed/refractory mantle cell lymphoma

Published:2021-03-11 Issue:4 Volume:21 Page:435-441
ISSN:1471-2598
Container-title:Expert Opinion on Biological Therapy
language:en
Short-container-title:Expert Opinion on Biological Therapy

Author:

Mian Agrima¹^ORCID,Hill Brian T.²³

Affiliation:

1. Department of Internal Medicine, Cleveland Clinic Foundation, Cleveland, OH, USA

2. Lymphoid Malignancies Program, Staff Physician, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland, OH, USA

3. Cleveland Clinic Lerner College of Medicine, Cleveland Clinic Foundation, Cleveland, OH, USA

Funder

funded

Publisher

Informa UK Limited

Subject

Clinical Biochemistry,Drug Discovery,Pharmacology

Link

https://www.tandfonline.com/doi/pdf/10.1080/14712598.2021.1889510

Reference44 articles.

1. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project

2. Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network

3. 2016 US lymphoid malignancy statistics by World Health Organization subtypes

4. Trends and variations in mantle cell lymphoma incidence from 1995 to 2013: A comparative study between Texas and National SEER areas

Cited by 46 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CD19 CAR-T treatment shows limited efficacy in r/r DLBCL with double expression and TP53 alterations;Cytotherapy;2024-07

2. The new era of immunological treatment, last updated and future consideration of CAR T cell-based drugs;Pharmacological Research;2024-05

3. CAR-T cell manufacturing: Major process parameters and next-generation strategies;Journal of Experimental Medicine;2024-01-16

4. Allogeneic CAR-T cells with of HLA-A/B and TRAC disruption exhibit promising antitumor capacity against B cell malignancies;Cancer Immunology, Immunotherapy;2024-01

5. Evolving CAR-T-Cell Therapy for Cancer Treatment: From Scientific Discovery to Cures;Cancers;2023-12-20

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3